Natasha Pinto Medici on her latest co–first author paper in @ScienceTransMed!
🚀 Her team introduces TMAB3 — a tumor-targeted, RNA-binding antibody that delivers RNA directly into tumors after systemic injection.
www.science.org/doi/10.1126/...
Natasha Pinto Medici on her latest co–first author paper in @ScienceTransMed!
🚀 Her team introduces TMAB3 — a tumor-targeted, RNA-binding antibody that delivers RNA directly into tumors after systemic injection.
www.science.org/doi/10.1126/...
We uncovered that #PI3K-driven wild-type RAS activation bypasses #KRAS inhibition in pancreatic adenocarcinoma (#PDAC) to drive #resistance.
🔑PI3K isn’t just a downstream RAS effector – it can be an upstream RAS regulator.
📄 www.biorxiv.org/content/10.1...